Incyte's JAK cream Opzelura proves its worth in treating hidradenitis suppurativa in midstage study

11 Mar 2024
www.fiercepharma.com
Clinical ResultPhase 3Phase 2Drug Approval
Opzelura is a cream version of Incyte's blockbuster Jakafi.
After a pair of approvals in reIncyteears and as itsJakafi continue to climb, Incyte's topical JAK inhibitor Opzelura is adding to its clinical case with trial results that demonstrate its benefits in patients with mild to moderate hidradenitis suppurativa (HS).
In a phase 2 study testing twice-daily Opzelura cream in patients with mild toIncyteate HS, invJAK inhibitorJAKigators notOpzeluragnificantly greater” reduction in patients’ abscesses and inflammatory nodule (AN) count after 16 weeks compared wihidradenitis suppurativa (HS)ntrol cream.
The disease is characterized by painfulOpzelura creambscesses that can cause irreversible tissue destruction and scarring.abscessesinflammatory nodule
The results, which the company shared in a presentatabscessesis year’s American Academy of Dermatology meeting, show “great potential” for patients with milder HS, Incyte's vice president of inflammation and autoimmunity, Jim Lee, M.D., Ph.D., said in a release.
“Despite its daily impact on the lives of patients, there are currently no approved therapies for mild-to-moderate HS and the current standard of care is often inadIncyte,” Lee added. “Today’inflammationsent autoimmunity step in progressing research for HS with the goal of being able to provide patients with an effective option to better manage their condition.”
The drug reduced total AN count by 50% or more in roughly 79% of patients, while more than 20% of patients who received the drug achieved complete clearance.
Plus, the majority of Opzelura patients met the criteria for Hidradenitis Suppurativa Clinical Response, a measure that includes a 50% or greater reduction in AN count without an increase in abscesses or draining fistulas.
Two patients did discontinue their participation in the studyHidradenitis Suppurativant-emergent adverse events were reported, Incyte said.abscesses
Opzelura is a cream version of Incyte’s blockbuster Jakafi and scored its original approval in 2021 for atopic dermatitis, addiIncytean indication for vitiligo the following year.
The med is currently the only tIncyte JAK inhibitor Jakafi U.S. market, but Leo Pharma and its contenderatopic dermatitisnd to put pressure on Incyte’svitiligoce. Recently, the company has been steadily reporting positive phase 3 studies of its JAK inhibitor cream in chronic hand eczema.
Elsewhere in Incyte’s JAK inhibitor arJAK inhibitorJAKal is its oral povorcitinib, which Leo Pharmad significant improdelgocitinibtch and disease severity iIncytease 2 study in prurigo nodularis.JAK inhibitorJAKchronic hand eczema
Opzelura is aIncyteingJAK inhibitorJAKsted in prurigo nodularis and ipovorcitinib be a rising star for Incyte. The drug brought iitch38 million in 2023 sales as “one of the bestprurigo nodularisgy launches,” the company's North American general manager Barry Flannelly said on the company’s fourth-quarter and full-year earnings conference call.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.